Company intelligence / Profile preview

Bioinduction

Bristol, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

The main program, using the Picostim DyNeuMo adaptive neurostimulator, has demonstrated initial safety and feasibility in first-in-human trials for mixed urinary incontinence, with results supporting advancement to pivotal studies. The technology also has extensive experience in deep brain stimulation indications, including Parkinson’s disease.[1][2][3][4][7]

Therapeutic areas: Women's HealthNeurology
Modalities: DeviceNeuromodulation therapyImplantable neurostimulator
Industry: Implantable Medical Devices

Partnerships

University of Oxford (academic/technology development)Academic partners for adaptive therapy development

Beyond the preview

Go deeper on Bioinduction.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioinduction.

Explore the full profile